Navigation Links
Malaria treatment efficacy compromised in certain HIV-positive patients

A weakened immune response resulting from HIV infection can lead to trouble when it comes to treating malaria, according to a new study appearing in the Oct. 1 issue of The Journal of Infectious Diseases, now available online.

"Our study demonstrates that HIV-1 infected patients with suppressed immunity represent, next to children and pregnant women, an additional vulnerable group for malaria," says Jean-Pierre Van geertruyden, MD, MSc, lead author of the article.

CD4 lymphocytes, white blood cells that serve a critical role in the immune response to malaria, are also the prime target for HIV. Low CD4 cell counts are a characteristic of HIV-induced immune suppression. In this study, Dr. Van geertruyden and colleagues from the Institute of Tropical Medicine in Belgium and the Tropical Disease Research Center in Zambia show that HIV-positive patients with low CD4 cell counts tended to have an increased risk of malaria treatment failure when compared to both HIV-negative patients and HIV-positive patients with higher CD4 cell counts.

Therefore, "HIV-1 associated immune suppression, rather than infection with HIV-1 per se, is the main determinant of malaria treatment outcome," says Dr. Van geertruyden.

This finding exposes a danger that implementing new malaria combination therapies to treat the disease in immune-suppressed patients could lead to the emergence and spread of antimalarial drug resistance. "This is a major concern, as antimalarial drug resistance is now generally acknowledged to be one of the greatest threats to our ability to roll back malaria," according to Dr. Van geertruyden.

The study suggests that malaria control and prevention, next to early diagnosis and a highly efficacious malaria treatment, are essential tools in areas where both diseases coexist. Furthermore, the interaction between antimalarial and antiretroviral therapies should continue to be examined in an effort to maximize the effects of therapy on both diseases and to decrease the malaria burden in HIV-infected individuals.


Source:Infectious Diseases Society of America

Related biology news :

1. Malaria mechanism revealed
2. Malaria killing a million a year
3. Malaria parasites develop in lymph nodes
4. Malaria, potato famine pathogen share surprising trait
5. Malaria vaccine prompts victims immune system to eliminate parasite from mosquitoes
6. Twenty Years of Malaria Research: Outcomes and Perspectives
7. Malaria may fuel spread of HIV in sub-Saharan Africa
8. Protein discovery could unlock the secret to better TB treatment
9. Topical treatment shown to inhibit HIV and herpes simplex virus infection
10. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
11. Researchers add new tool to tumor-treatment arsenal
Post Your Comments:

(Date:9/30/2015)... , Sept. 30, 2015  The U.S. Court ... issued another key ruling in favor of Crossmatch ... Korean fingerprint scanner company Suprema and its U.S. partner ... 1930, a trade provision that declares it unlawful to ... by infringing two of Crossmatch,s patents, the 5,900,993 patent ...
(Date:9/29/2015)... , Sept. 29, 2015  iDAvatars is excited to be ... its product to market. The official announcement was recently made ... event in San Francisco , where ... powered by IBM Watson. "It is both an ... 100 companies to bring to market the cognitive power of ...
(Date:9/28/2015)... The global image sensors ... billion by 2020, growing at a CAGR of 4.6% ... Illumination (BSI) technique to improve picture quality are expected ...      (Logo: , The light ... loss and, thus, reduce the noise interference and increase ...
Breaking Biology News(10 mins):
(Date:10/9/2015)... ANNAPOLIS, Md. , Oct. 9, 2015 ... entered into the Congressional Record her statement recognizing the ... celebrated October 11-17. IPAW is sponsored by the ... companies, and is designed to:   , Raise ... contributions of plasma donors in saving and improving lives ...
(Date:10/9/2015)... and ROCKVILLE, Md. , Oct. ... privately-held biotechnology company developing next generation vaccines based ... has entered into an exclusive worldwide licensing agreement ... the treatment or prevention of any and all ... agreement, Immunomic Therapeutics will receive an upfront payment ...
(Date:10/9/2015)... Inc., (NASDAQ: PULM ) will be webcasting the Company,s ... th Annual BIO Investor Forum on Tuesday, October 20, ... --> th Annual BIO Investor Forum on Tuesday, ... --> Pulmatrix will be presenting at the ... October 15, 2015 at 8:30 am EDT. Additionally, the Company ...
(Date:10/9/2015)... ... 09, 2015 , ... Leading microbial genomics startup uBiome today launched the first-ever ... between weight management and the microbiome. The study uses the ResearchKit framework, designed by ... app. , The uBiome app is available as a free download from the App ...
Breaking Biology Technology: